Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer

Pancreas

Volumn 38, Issue 3, 2009, Pages 330-337

  Graeser, Ralph ^a,c   Bornmann, Christian ^a   Esser, Norbert ^a   Ziroli, Vittorio ^b   Jantscheff, Peter ^b   Unger, Clemens ^b   Hopt, Ulrich T ^a   Schaechtele, Christoph ^a   Von Dobschuetz, Ernst ^a   Massing, Ulrich ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b TUMOR BIOLOGY CENTER   (Germany)

^c PROQINASE GMBH   (Germany)

Author keywords

Gemcitabine; In vivo bioluminescence imaging; Liposomes; Pancreatic cancer

Indexed keywords

GEMCITABINE; LIPOSOME; LUCIFERASE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BIOLUMINESCENCE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ASSAY; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS; PANCREAS CANCER; PANCREAS TUMOR; PERITONEUM METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTECTION; SPLEEN; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; DRUG RESISTANCE; GENETIC TRANSDUCTION; GENETICS; METASTASIS; PATHOLOGY; PERITONEUM TUMOR;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; LIPOSOMES; LUCIFERASES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; TRANSDUCTION, GENETIC;

EID: 65549125858     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31819436e6     Document Type: Article

References (42)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Noble S, Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997;54:447-472.
3. Axelson J, Lindell M, Horlin K, et al. Inhibition of different intracellular signal cascades in human pancreatic cancer cells. Pancreatology. 2005;5:251-258.
4. Zagon IS, Jaglowski JR, Verderame MF, et al. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2005;56: 510-520.
5. Moog R, Burger AM, Brandl M, et al. Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer Chemother Pharmacol. 2002;49:356-366.
6. Schueler J. Entwicklung und Charakterisierung humaner Tumormodelle durch orthotope Implantation Inst für Veterinärpathologie. Berlin, Germany: Freie Universität; 1998.
7. Bornmann C, Graeser R, Esser N, et al. A new liposomal formulation of gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging. Cancer Chemother Pharmacol. 2008;61:395-405.
8. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752-3756.
9. Massing U. Cancer therapy with liposomal formulations of anticancer drugs. Int J Clin Pharmacol Ther. 1997;35:87-90.
10. Massing U, Fuxius S. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist Updat. 2000;3:171-177.
11. Ludemann L, Grieger W, Wurm R, et al. Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn Reson Imaging. 2005;23:833-841.
12. Hotz HG, Reber HA, Hotz B, et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas. 2003;26:e89-e98.
13. Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res. 2003; 9:346-354.
14. Stephan S, Datta K, Wang E, et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res. 2004;10:6993-7000.
15. Workman P, Balmain A, Hickman JA, et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim. 1988; 22:195-201.
16. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol. 1999;6:279-285.
17. Braakhuis BJ, van Dongen GA, Vermorken JB, et al. Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res. 1991;51:211-214.
18. Oettle H, Riess H. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer. 2002;95:912-922.
19. Bondar VM, Sweeney-Gotsch B, Andreeff M, et al. Inhibition of the phosphatidylinositol 3-kinaseYAKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2002;1:989-997.
20. Allen T, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 1987;223:42-46.
21. Svanborg A, Svennerholm L. Plasma total lipid, cholesterol, triglycerides, phospholipids and free fatty acids in a healthy Scandinavian population. Acta Med Scand. 1961;169:43.
22. Mead JF, Alfin-Slater RB, Howton DR, et al. Lipids - Chemistry, Biochemistry and Nutrition. New York, NY: Plenum Press; 1986.
23. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-167.
24. Kashiwagi M, Friess H, Uhl W, et al. Group II and IV phospholipase A(2) are produced in human pancreatic cancer cells and influence prognosis. Gut. 1999;45:605-612.
25. Aoki J, Inoue A, Makide K, et al. Structure and function of extracellular phospholipase A1 belonging to the pancreatic lipase gene family. Biochimie. 2007;89:197-204.
26. Chen S, Subbaiah PV. Phospholipid and fatty acid specificity of endothelial lipase: potential role of the enzyme in the delivery of docosahexaenoic acid (DHA) to tissues. Biochim Biophys Acta. 2007;1771:1319-1328.
27. Havel RJ, Goldstein JL, Brown MS. Lipoproteins and lipid transport. In: Bondy PK, Rosenberg LE, eds. Metabolic Control and Disease. 8th ed. Philadelphia, PA: WB Saunders; 1980:373-494.
28. Taylor LA, Arends J, Hodina AK, et al. Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis. 2007;6:17.
29. Hildenbrand B, Kley J, Haberstroh F, et al. Cytotoxic efficacy and influence on cellular phospholipid metabolism of 2-hydroxy- and 2-O-acetyl-octadecylphosphocholines. Anticancer Res. 2006; 26:4255-4262.
30. Baburina I, Jackowski S. Apoptosis triggered by 1-O-octadecyl-2-O-methyl- rac-glycero-3-phosphocholine is prevented by increased expression of CTP:phosphocholine cytidylyltransferase. J Biol Chem. 1998;273:2169-2173.
31. Wang D, Dubois R. Prostaglandins and cancer. Gut. 2006;55:115-122.
32. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000;21:139-146.
33. Jiang J, Chen C, Card J, et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 2005;65:4707-4715.
34. Jiang JG, Ning YG, Chen C, et al. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res. 2007;67:6665-6674.
35. Standop J, Schneider M, Ulrich A, et al. Differences in immunohistochemical expression of xenobiotic-metabolizing enzymes between normal pancreas, chronic pancreatitis and pancreatic cancer. Toxicol Pathol. 2003;31:506-513.
36. Ding X, Iversen P, Cluck M, et al. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun. 1999;261:218-223.
37. Hennig R, Ding X, Tong W, et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol. 2002;161:421-428.
38. Ding X, Hennig R, Adrian T. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol Cancer. 2003;2:10.
39. Dini L, Falasca L, Ruzzittu M, et al. Interaction between isolated and purified liver cells and small unilamellar liposomes. Liver. 1998; 18:229-238.
40. Laverman P, Dams E, Storm G, et al. Microscopic localization of PEG-liposomes in a rat model of focal infection. J Control Release. 2001;75:347-355.
41. Moghimi S, Patel H. Modulation of murine liver macrophage clearance of liposomes by diethylstilbestrol. The effect of vesicle surface charge and a role for the complement receptor Mac-1 (CD11b/CD18) of newly recruited macrophages in liposome recognition. J Control Release. 2002;78:55-65.
42. Dobreva I, Zschornig O, Waeber G, et al. Cholesterol is the major component of native lipoproteins activating the p38 mitogen-activated protein kinases. Biol Chem. 2005;386:909-918.